Targeting MET Amplification as a New Oncogenic Driver

MET amplification as a potential therapeutic target in gastric cancer

(2015) Hisato Kawakami et al.   Oncotarget

Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study

(2015) Isamu Okamoto et al.   Oncotarget

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

(2014) Y J Liu et al.   BRITISH JOURNAL OF CANCER

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

(2013) R. Katayama et al.   CANCER RESEARCH

c-MET kinase inhibitors: a patent review (2011 – 2013)

(2013) Kongkai Zhu et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Statins and the Risk of Death in Patients With Prostate Cancer

(2013) Oriana Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

(2013) Richard Schwab et al.   LUNG CANCER

Frequent Gene Amplification Predicts Poor Prognosis in Gastric Cancer

(2012) Jing Shi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

(2012) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

(2012) H. Y. Zou et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

(2012) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

(2012) Nathan V. Lee et al.   PLoS One

MET Expression and Amplification in Patients with Localized Gastric Cancer

(2011) Y. Y. Janjigian et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer

(2011) Francesco Graziano et al.   JOURNAL OF CLINICAL ONCOLOGY

METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

(2011) Jochen K. Lennerz et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor

(2011) Andrew S. Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

(2011) Junko Tanizaki et al.   Journal of Thoracic Oncology

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma

(2010) I. J. Davis et al.   CANCER RESEARCH

Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency

(2010) U. McDermott et al.   CANCER RESEARCH

MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors

(2010) V. Cepero et al.   CANCER RESEARCH

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

Small molecule c-Met kinase inhibitors: a review of recent patents

(2010) John Porter   EXPERT OPINION ON THERAPEUTIC PATENTS

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

(2010) Heounjeong Go et al.   Journal of Thoracic Oncology

Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors

(2009) Sergei L. Timofeevski et al.   BIOCHEMISTRY

IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

(2009) Federico Cappuzzo et al.   JOURNAL OF CLINICAL ONCOLOGY

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

(2009) Michèle Beau-Faller et al.   Journal of Thoracic Oncology

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

(2009) Takamitsu Onitsuka et al.   LUNG CANCER

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

(2008) Katsuhiro Okuda et al.   CANCER SCIENCE

METgene amplification orEGFRmutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

(2008) Takafumi Kubo et al.   INTERNATIONAL JOURNAL OF CANCER

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing

(2008) Isabelle Vanden Bempt et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY